{
    "id": 8564,
    "name": "lip cancer",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "8563",
        "9135",
        "9031",
        "8605",
        "8975"
    ],
    "termId": "DOID:8564",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02795156",
            "title": "Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                },
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03422536",
            "title": "Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 740,
                    "therapyName": "Ficlatuzumab",
                    "synonyms": null
                },
                {
                    "id": 1959,
                    "therapyName": "Cetuximab + Ficlatuzumab",
                    "synonyms": null
                }
            ]
        }
    ]
}